Page 1,028«..1020..1,0271,0281,0291,030..1,0401,050..»

Anti-Trans Laws Are Preventing Trans Women From Playing on Womens Sports Teams – Teen Vogue

Posted: May 18, 2020 at 11:48 am

Sign the ACLU's petition to support trans student athletes.

Growing up, I never felt like I fit in. I was trying to be this cool, masculine, teenage boy, but I felt like I was faking it. In high school, I secretly shopped for girls clothes at Goodwill and would put them on after school. But when I looked in the mirror, I was so disappointed. I didnt understand it at the time, but what I was experiencing was gender dysphoria, a deeply painful feeling that comes from knowing that your sex assigned at birth and your body do not reflect your true gender.

One solace during this confusing time was running. Running was always my passion, but it was only after I joined the cross-country team that I found a community. The four years I spent on my high school track-and-field team and the three years I spent on the cross-country team were the best part of high school. My teammates became my whole friend group, my coaches were my mentors, and the discipline of group practices helped me focus better on my schoolwork. Running with a team gave me confidence, made me feel good, and also helped me forget about my sadness and internal struggles.

At the end of my senior year of high school, I took a major, life-affirming step that seemed sudden but was a long time coming: I came out to myself as trans. With college imminent, I could imagine myself becoming the person I wanted to be the person I am. That summer, I began aligning my body with my female gender and soon after started hormone replacement therapy.

When I started college last fall at Boise State University I took solo runs, but I didnt try out for track or cross-country. I needed some time to become comfortable with my new identity and college life.

Besides, I couldnt have tried out even if Id wanted to. The National Collegiate Athletic Association (NCAA) requires women who are transgender like me to complete 12 months of hormone therapy to suppress testosterone as part of their gender transition before competing. I was already doing this because I needed it for my health, and I knew that by the start of my sophomore year I would be ready to compete again when eligible in the fall of 2020.

And then something devastating happened.

Earlier this year, Idaho legislators introduced HB 500, which not only banned trans girls and women athletes from competing on their school teams, but exposed all girls and women to invasive, intrusive genital testing if anyone challenges their gender. I joined activists and community members in speaking out against the bill at the statehouse, but it passed anyway. On the eve of March 31, Trans Visibility Day, Governor Brad Little signed the bill into law. That meant I could no longer try out for the Boise State track or cross-country teams or participate on any of my universitys sports teams even club or intramural ones.

So I decided to fight for myself and for all the trans and intersex student athletes across Idaho, as well as for all Idaho girls and women athletes, who shouldnt be subject to invasive sex verification exams in order to play school sports. On April 15, a team of lawyers from Legal Voice, the American Civil Liberties Union, and Cooley LLP filed a lawsuit challenging the constitutionality of the bill because it invades young peoples privacy and because it discriminates based on sex.

Read more:
Anti-Trans Laws Are Preventing Trans Women From Playing on Womens Sports Teams - Teen Vogue

Posted in Testosterone Replacement Therapy | Comments Off on Anti-Trans Laws Are Preventing Trans Women From Playing on Womens Sports Teams – Teen Vogue

Hormone Replacement Therapy Market Outlook,Deep Research Report Stydy,Share and perfect Year to Year CAGR Analysis With Forecast Period 2020 to…

Posted: May 18, 2020 at 11:48 am

Los Angeles, United StatesThe report offers an all-inclusive and accurate research study on the global Hormone Replacement Therapy market while chiefly focusing on current and historical market scenarios. Stakeholders, market players, investors, and other market participants can significantly benefit from the thorough market analysis provided in the report. The authors of the report have compiled a detailed study on crucial market dynamics, including growth drivers, restraints, and opportunities. This study will help market participants to get a good understanding of future development of the global Hormone Replacement Therapy market. The report also focuses on market taxonomy, regional analysis, opportunity assessment, and vendor analysis to help with comprehensive evaluation of the global Hormone Replacement Therapy market.

Key companies operating in the global Hormone Replacement Therapy market include : , Eli Lilly, Pfizer, AbbVie, Novo Nordisk, Merck KGaA, Mylan, Bayer, Teva, Novartis, Abbott, Roche, Endo International, Ipsen, ANI Pharmaceuticals, TherapeuticsMD Hormone Replacement Therapy

Get PDF Sample Copy of the Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) :

https://www.qyresearch.com/sample-form/form/1706851/covid-19-impact-on-global-hormone-replacement-therapy-market

Segment Analysis

The segmental analysis will help companies to focus on high-growth areas of the global Hormone Replacement Therapy market. In order to broaden the overall understanding of the global Hormone Replacement Therapy industry, the report has segregated the global Hormone Replacement Therapy business into varied segments comprising product type, application, and end user. This examination has been carried out based on parameters like size, CAGR, share, production, and consumption. Also, region-wise assessment, wherein lucrative prospects that a region or country is likely to offer has been explored.

Global Hormone Replacement Therapy Market Segment By Type:

, Estrogen Hormone, Growth Hormone, Thyroid Hormone, Testosterone Hormone, The proportion of estrogen hormone in 2018 is about 50%, and the proportion is in increasing trend from 2014 to 2018. Hormone Replacement Therapy

Global Hormone Replacement Therapy Market Segment By Application:

, Estrogen Hormone, Growth Hormone, Thyroid Hormone, Testosterone Hormone, The proportion of estrogen hormone in 2018 is about 50%, and the proportion is in increasing trend from 2014 to 2018. Hormone Replacement Therapy

Competitive Landscape:

It is important for every market participant to be familiar with the competitive scenario in the global Hormone Replacement Therapy industry. In order to fulfill the requirements, the industry analysts have evaluated the strategic activities of the competitors to help the key players strengthen their foothold in the market and increase their competitiveness.

Key companies operating in the global Hormone Replacement Therapy market include : , Eli Lilly, Pfizer, AbbVie, Novo Nordisk, Merck KGaA, Mylan, Bayer, Teva, Novartis, Abbott, Roche, Endo International, Ipsen, ANI Pharmaceuticals, TherapeuticsMD Hormone Replacement Therapy

Key Questions Answered

Enquire for Customization in this Report: https://www.qyresearch.com/customize-request/form/1706851/covid-19-impact-on-global-hormone-replacement-therapy-market

Table of Contents

1 Study Coverage1.1 Hormone Replacement Therapy Product Introduction1.2 Market Segments1.3 Key Hormone Replacement Therapy Manufacturers Covered: Ranking by Revenue1.4 Market by Type1.4.1 Global Hormone Replacement Therapy Market Size Growth Rate by Type1.4.2 Estrogen Hormone1.4.3 Growth Hormone1.4.4 Thyroid Hormone1.4.5 Testosterone Hormone1.5 Market by Application1.5.1 Global Hormone Replacement Therapy Market Size Growth Rate by Application1.5.2 Menopause1.5.3 Hypothyroidism1.5.4 Growth Hormone Deficiency1.5.5 Male Hypogonadism1.5.6 Other Diseases1.6 Coronavirus Disease 2019 (Covid-19): Hormone Replacement Therapy Industry Impact1.6.1 How the Covid-19 is Affecting the Hormone Replacement Therapy Industry

1.6.1.1 Hormone Replacement Therapy Business Impact Assessment Covid-19

1.6.1.2 Supply Chain Challenges

1.6.1.3 COVID-19s Impact On Crude Oil and Refined Products1.6.2 Market Trends and Hormone Replacement Therapy Potential Opportunities in the COVID-19 Landscape1.6.3 Measures / Proposal against Covid-19

1.6.3.1 Government Measures to Combat Covid-19 Impact

1.6.3.2 Proposal for Hormone Replacement Therapy Players to Combat Covid-19 Impact1.7 Study Objectives1.8 Years Considered 2 Executive Summary2.1 Global Hormone Replacement Therapy Market Size Estimates and Forecasts2.1.1 Global Hormone Replacement Therapy Revenue 2015-20262.1.2 Global Hormone Replacement Therapy Sales 2015-20262.2 Hormone Replacement Therapy Market Size by Region: 2020 Versus 20262.2.1 Global Hormone Replacement Therapy Retrospective Market Scenario in Sales by Region: 2015-20202.2.2 Global Hormone Replacement Therapy Retrospective Market Scenario in Revenue by Region: 2015-2020 3 Global Hormone Replacement Therapy Competitor Landscape by Players3.1 Hormone Replacement Therapy Sales by Manufacturers3.1.1 Hormone Replacement Therapy Sales by Manufacturers (2015-2020)3.1.2 Hormone Replacement Therapy Sales Market Share by Manufacturers (2015-2020)3.2 Hormone Replacement Therapy Revenue by Manufacturers3.2.1 Hormone Replacement Therapy Revenue by Manufacturers (2015-2020)3.2.2 Hormone Replacement Therapy Revenue Share by Manufacturers (2015-2020)3.2.3 Global Hormone Replacement Therapy Market Concentration Ratio (CR5 and HHI) (2015-2020)3.2.4 Global Top 10 and Top 5 Companies by Hormone Replacement Therapy Revenue in 20193.2.5 Global Hormone Replacement Therapy Market Share by Company Type (Tier 1, Tier 2 and Tier 3)3.3 Hormone Replacement Therapy Price by Manufacturers3.4 Hormone Replacement Therapy Manufacturing Base Distribution, Product Types3.4.1 Hormone Replacement Therapy Manufacturers Manufacturing Base Distribution, Headquarters3.4.2 Manufacturers Hormone Replacement Therapy Product Type3.4.3 Date of International Manufacturers Enter into Hormone Replacement Therapy Market3.5 Manufacturers Mergers & Acquisitions, Expansion Plans 4 Breakdown Data by Type (2015-2026)4.1 Global Hormone Replacement Therapy Market Size by Type (2015-2020)4.1.1 Global Hormone Replacement Therapy Sales by Type (2015-2020)4.1.2 Global Hormone Replacement Therapy Revenue by Type (2015-2020)4.1.3 Hormone Replacement Therapy Average Selling Price (ASP) by Type (2015-2026)4.2 Global Hormone Replacement Therapy Market Size Forecast by Type (2021-2026)4.2.1 Global Hormone Replacement Therapy Sales Forecast by Type (2021-2026)4.2.2 Global Hormone Replacement Therapy Revenue Forecast by Type (2021-2026)4.2.3 Hormone Replacement Therapy Average Selling Price (ASP) Forecast by Type (2021-2026)4.3 Global Hormone Replacement Therapy Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End 5 Breakdown Data by Application (2015-2026)5.1 Global Hormone Replacement Therapy Market Size by Application (2015-2020)5.1.1 Global Hormone Replacement Therapy Sales by Application (2015-2020)5.1.2 Global Hormone Replacement Therapy Revenue by Application (2015-2020)5.1.3 Hormone Replacement Therapy Price by Application (2015-2020)5.2 Hormone Replacement Therapy Market Size Forecast by Application (2021-2026)5.2.1 Global Hormone Replacement Therapy Sales Forecast by Application (2021-2026)5.2.2 Global Hormone Replacement Therapy Revenue Forecast by Application (2021-2026)5.2.3 Global Hormone Replacement Therapy Price Forecast by Application (2021-2026) 6 North America6.1 North America Hormone Replacement Therapy by Country6.1.1 North America Hormone Replacement Therapy Sales by Country6.1.2 North America Hormone Replacement Therapy Revenue by Country6.1.3 U.S.6.1.4 Canada6.2 North America Hormone Replacement Therapy Market Facts & Figures by Type6.3 North America Hormone Replacement Therapy Market Facts & Figures by Application 7 Europe7.1 Europe Hormone Replacement Therapy by Country7.1.1 Europe Hormone Replacement Therapy Sales by Country7.1.2 Europe Hormone Replacement Therapy Revenue by Country7.1.3 Germany7.1.4 France7.1.5 U.K.7.1.6 Italy7.1.7 Russia7.2 Europe Hormone Replacement Therapy Market Facts & Figures by Type7.3 Europe Hormone Replacement Therapy Market Facts & Figures by Application 8 Asia Pacific8.1 Asia Pacific Hormone Replacement Therapy by Region8.1.1 Asia Pacific Hormone Replacement Therapy Sales by Region8.1.2 Asia Pacific Hormone Replacement Therapy Revenue by Region8.1.3 China8.1.4 Japan8.1.5 South Korea8.1.6 India8.1.7 Australia8.1.8 Taiwan8.1.9 Indonesia8.1.10 Thailand8.1.11 Malaysia8.1.12 Philippines8.1.13 Vietnam8.2 Asia Pacific Hormone Replacement Therapy Market Facts & Figures by Type8.3 Asia Pacific Hormone Replacement Therapy Market Facts & Figures by Application 9 Latin America9.1 Latin America Hormone Replacement Therapy by Country9.1.1 Latin America Hormone Replacement Therapy Sales by Country9.1.2 Latin America Hormone Replacement Therapy Revenue by Country9.1.3 Mexico9.1.4 Brazil9.1.5 Argentina9.2 Central & South America Hormone Replacement Therapy Market Facts & Figures by Type9.3 Central & South America Hormone Replacement Therapy Market Facts & Figures by Application 10 Middle East and Africa10.1 Middle East and Africa Hormone Replacement Therapy by Country10.1.1 Middle East and Africa Hormone Replacement Therapy Sales by Country10.1.2 Middle East and Africa Hormone Replacement Therapy Revenue by Country10.1.3 Turkey10.1.4 Saudi Arabia10.1.5 UAE10.2 Middle East and Africa Hormone Replacement Therapy Market Facts & Figures by Type10.3 Middle East and Africa Hormone Replacement Therapy Market Facts & Figures by Application 11 Company Profiles11.1 Eli Lilly11.1.1 Eli Lilly Corporation Information11.1.2 Eli Lilly Description, Business Overview and Total Revenue11.1.3 Eli Lilly Sales, Revenue and Gross Margin (2015-2020)11.1.4 Eli Lilly Hormone Replacement Therapy Products Offered11.1.5 Eli Lilly Recent Development11.2 Pfizer11.2.1 Pfizer Corporation Information11.2.2 Pfizer Description, Business Overview and Total Revenue11.2.3 Pfizer Sales, Revenue and Gross Margin (2015-2020)11.2.4 Pfizer Hormone Replacement Therapy Products Offered11.2.5 Pfizer Recent Development11.3 AbbVie11.3.1 AbbVie Corporation Information11.3.2 AbbVie Description, Business Overview and Total Revenue11.3.3 AbbVie Sales, Revenue and Gross Margin (2015-2020)11.3.4 AbbVie Hormone Replacement Therapy Products Offered11.3.5 AbbVie Recent Development11.4 Novo Nordisk11.4.1 Novo Nordisk Corporation Information11.4.2 Novo Nordisk Description, Business Overview and Total Revenue11.4.3 Novo Nordisk Sales, Revenue and Gross Margin (2015-2020)11.4.4 Novo Nordisk Hormone Replacement Therapy Products Offered11.4.5 Novo Nordisk Recent Development11.5 Merck KGaA11.5.1 Merck KGaA Corporation Information11.5.2 Merck KGaA Description, Business Overview and Total Revenue11.5.3 Merck KGaA Sales, Revenue and Gross Margin (2015-2020)11.5.4 Merck KGaA Hormone Replacement Therapy Products Offered11.5.5 Merck KGaA Recent Development11.6 Mylan11.6.1 Mylan Corporation Information11.6.2 Mylan Description, Business Overview and Total Revenue11.6.3 Mylan Sales, Revenue and Gross Margin (2015-2020)11.6.4 Mylan Hormone Replacement Therapy Products Offered11.6.5 Mylan Recent Development11.7 Bayer11.7.1 Bayer Corporation Information11.7.2 Bayer Description, Business Overview and Total Revenue11.7.3 Bayer Sales, Revenue and Gross Margin (2015-2020)11.7.4 Bayer Hormone Replacement Therapy Products Offered11.7.5 Bayer Recent Development11.8 Teva11.8.1 Teva Corporation Information11.8.2 Teva Description, Business Overview and Total Revenue11.8.3 Teva Sales, Revenue and Gross Margin (2015-2020)11.8.4 Teva Hormone Replacement Therapy Products Offered11.8.5 Teva Recent Development11.9 Novartis11.9.1 Novartis Corporation Information11.9.2 Novartis Description, Business Overview and Total Revenue11.9.3 Novartis Sales, Revenue and Gross Margin (2015-2020)11.9.4 Novartis Hormone Replacement Therapy Products Offered11.9.5 Novartis Recent Development11.10 Abbott11.10.1 Abbott Corporation Information11.10.2 Abbott Description, Business Overview and Total Revenue11.10.3 Abbott Sales, Revenue and Gross Margin (2015-2020)11.10.4 Abbott Hormone Replacement Therapy Products Offered11.10.5 Abbott Recent Development11.1 Eli Lilly11.1.1 Eli Lilly Corporation Information11.1.2 Eli Lilly Description, Business Overview and Total Revenue11.1.3 Eli Lilly Sales, Revenue and Gross Margin (2015-2020)11.1.4 Eli Lilly Hormone Replacement Therapy Products Offered11.1.5 Eli Lilly Recent Development11.12 Endo International11.12.1 Endo International Corporation Information11.12.2 Endo International Description, Business Overview and Total Revenue11.12.3 Endo International Sales, Revenue and Gross Margin (2015-2020)11.12.4 Endo International Products Offered11.12.5 Endo International Recent Development11.13 Ipsen11.13.1 Ipsen Corporation Information11.13.2 Ipsen Description, Business Overview and Total Revenue11.13.3 Ipsen Sales, Revenue and Gross Margin (2015-2020)11.13.4 Ipsen Products Offered11.13.5 Ipsen Recent Development11.14 ANI Pharmaceuticals11.14.1 ANI Pharmaceuticals Corporation Information11.14.2 ANI Pharmaceuticals Description, Business Overview and Total Revenue11.14.3 ANI Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020)11.14.4 ANI Pharmaceuticals Products Offered11.14.5 ANI Pharmaceuticals Recent Development11.15 TherapeuticsMD11.15.1 TherapeuticsMD Corporation Information11.15.2 TherapeuticsMD Description, Business Overview and Total Revenue11.15.3 TherapeuticsMD Sales, Revenue and Gross Margin (2015-2020)11.15.4 TherapeuticsMD Products Offered11.15.5 TherapeuticsMD Recent Development 12 Future Forecast by Regions (Countries) (2021-2026)12.1 Hormone Replacement Therapy Market Estimates and Projections by Region12.1.1 Global Hormone Replacement Therapy Sales Forecast by Regions 2021-202612.1.2 Global Hormone Replacement Therapy Revenue Forecast by Regions 2021-202612.2 North America Hormone Replacement Therapy Market Size Forecast (2021-2026)12.2.1 North America: Hormone Replacement Therapy Sales Forecast (2021-2026)12.2.2 North America: Hormone Replacement Therapy Revenue Forecast (2021-2026)12.2.3 North America: Hormone Replacement Therapy Market Size Forecast by Country (2021-2026)12.3 Europe Hormone Replacement Therapy Market Size Forecast (2021-2026)12.3.1 Europe: Hormone Replacement Therapy Sales Forecast (2021-2026)12.3.2 Europe: Hormone Replacement Therapy Revenue Forecast (2021-2026)12.3.3 Europe: Hormone Replacement Therapy Market Size Forecast by Country (2021-2026)12.4 Asia Pacific Hormone Replacement Therapy Market Size Forecast (2021-2026)12.4.1 Asia Pacific: Hormone Replacement Therapy Sales Forecast (2021-2026)12.4.2 Asia Pacific: Hormone Replacement Therapy Revenue Forecast (2021-2026)12.4.3 Asia Pacific: Hormone Replacement Therapy Market Size Forecast by Region (2021-2026)12.5 Latin America Hormone Replacement Therapy Market Size Forecast (2021-2026)12.5.1 Latin America: Hormone Replacement Therapy Sales Forecast (2021-2026)12.5.2 Latin America: Hormone Replacement Therapy Revenue Forecast (2021-2026)12.5.3 Latin America: Hormone Replacement Therapy Market Size Forecast by Country (2021-2026)12.6 Middle East and Africa Hormone Replacement Therapy Market Size Forecast (2021-2026)12.6.1 Middle East and Africa: Hormone Replacement Therapy Sales Forecast (2021-2026)12.6.2 Middle East and Africa: Hormone Replacement Therapy Revenue Forecast (2021-2026)12.6.3 Middle East and Africa: Hormone Replacement Therapy Market Size Forecast by Country (2021-2026) 13 Market Opportunities, Challenges, Risks and Influences Factors Analysis13.1 Market Opportunities and Drivers13.2 Market Challenges13.3 Market Risks/Restraints13.4 Porters Five Forces Analysis13.5 Primary Interviews with Key Hormone Replacement Therapy Players (Opinion Leaders) 14 Value Chain and Sales Channels Analysis14.1 Value Chain Analysis14.2 Hormone Replacement Therapy Customers14.3 Sales Channels Analysis14.3.1 Sales Channels14.3.2 Distributors 15 Research Findings and Conclusion 16 Appendix16.1 Research Methodology16.1.1 Methodology/Research Approach16.1.2 Data Source16.2 Author Details

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from the huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become a brand of quality assurance in the consulting industry.

More here:
Hormone Replacement Therapy Market Outlook,Deep Research Report Stydy,Share and perfect Year to Year CAGR Analysis With Forecast Period 2020 to...

Posted in Testosterone Replacement Therapy | Comments Off on Hormone Replacement Therapy Market Outlook,Deep Research Report Stydy,Share and perfect Year to Year CAGR Analysis With Forecast Period 2020 to…

Analysis on Impact of COVID-19-Stem Cell Therapy Market 2020-2024 | Increase in Awareness of Stem Cell Therapy to Boost Growth | Technavio – Business…

Posted: May 18, 2020 at 11:46 am

LONDON--(BUSINESS WIRE)--Technavio has been monitoring the stem cell therapy market and it is poised to grow by USD 588.22 million during 2020-2024, progressing at a CAGR of almost 7% during the forecast period. The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment.

Technavio suggests three forecast scenarios (optimistic, probable, and pessimistic) considering the impact of COVID-19. Please Request Free Sample Report on COVID-19 Impact

The market is fragmented, and the degree of fragmentation will accelerate during the forecast period. Gilead Sciences Inc., Holostem Terapie Avanzate Srl, Lineage Cell Therapeutics Inc., Lonza Group Ltd., Novartis AG, Nuvasive Inc., Organogenesis Inc., Osiris Therapeutics Inc., RTI Surgical Holdings Inc., and Vericel Corp. are some of the major market participants. The increase in awareness of stem cell therapy will offer immense growth opportunities. To make the most of the opportunities, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.

Increase in awareness of stem cell therapy has been instrumental in driving the growth of the market.

Stem Cell Therapy Market 2020-2024: Segmentation

Stem Cell Therapy Market is segmented as below:

To learn more about the global trends impacting the future of market research, download a free sample: https://www.technavio.com/talk-to-us?report=IRTNTR43432

Stem Cell Therapy Market 2020-2024: Scope

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources. Our stem cell therapy market report covers the following areas:

This study identifies limited number of FDA-approved stem cell therapies as one of the prime reasons driving the stem cell therapy market growth during the next few years.

Stem Cell Therapy Market 2020-2024: Vendor Analysis

We provide a detailed analysis of vendors operating in the stem cell therapy market, including some of the vendors such as Gilead Sciences Inc., Holostem Terapie Avanzate Srl, Lineage Cell Therapeutics Inc., Lonza Group Ltd., Novartis AG, Nuvasive Inc., Organogenesis Inc., Osiris Therapeutics Inc., RTI Surgical Holdings Inc., and Vericel Corp. Backed with competitive intelligence and benchmarking, our research reports on the stem cell therapy market are designed to provide entry support, customer profile and M&As as well as go-to-market strategy support.

Register for a free trial today and gain instant access to 17,000+ market research reports.

Technavio's SUBSCRIPTION platform

Stem Cell Therapy Market 2020-2024: Key Highlights

Table Of Contents:

Executive Summary

Market Landscape

Market Sizing

Five Forces Analysis

Market Segmentation by Type

Customer landscape

Geographic Landscape

Market Drivers

Market Challenges

Market Trends

Vendor Landscape

Vendor Analysis

Appendix

About Us

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavios report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavios comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

See the article here:
Analysis on Impact of COVID-19-Stem Cell Therapy Market 2020-2024 | Increase in Awareness of Stem Cell Therapy to Boost Growth | Technavio - Business...

Posted in Stem Cell Therapy | Comments Off on Analysis on Impact of COVID-19-Stem Cell Therapy Market 2020-2024 | Increase in Awareness of Stem Cell Therapy to Boost Growth | Technavio – Business…

Unproven stem cell products are being peddled as COVID-19 ‘therapies,’ U of M researcher reports – MinnPost

Posted: May 18, 2020 at 11:46 am

Coronavirus health scams are rampant, with businesses taking advantage of peoples fears to sell all sorts of unproven products for the prevention and treatment of COVID-19. Some of these snake oil cures are innocuous, such as elderberry juice, but others can be harmful, such as colloidal silver.

Among the products with considerable potential for harm are unproven stem cell therapies. Unfortunately, the emergence of this particular line of sham COVID-19 treatments isnt all that surprising. For more than a decade, businesses have been aggressively pitching unsubstantiated and unlicensed stem cell products to vulnerable and often desperate individuals with illnesses or injuries for which no known treatment exists, such as Alzheimers disease, amyotrophic lateral sclerosis (ALS), chronic obstructive pulmonary disease (COPD) and spinal cord injuries. The results have sometimes been deadly.

There are some medical conditions for which stem cell therapies have been shown to be safe and effective, but they are few in number mostly cancer and several blood and immune disorders.

Leigh Turner, a bioethicist at the University of Minnesota, has been investigating the direct-to-consumer marketing of spurious stem cell therapies and related exosome products in the United States for nearly a decade. In an article published recently in the journal Cell Stem Cell, Leigh describes the latest twist in this cynical saga: how some stem cell businesses are seizing the [COVID-19] pandemic as an opportunity to profit from hope and desperation.

MinnPost spoke with Turner late last week about what he found when researching that paper. The following is an edited transcript of the interview.

MinnPost: Companies seem to be using the same kind of marketing strategies to sell unproven stem cell therapies for COVID-19 as they have for other medical conditions.

Leigh Turner: Yes. These are opportunistic businesses. They look for marketplace opportunities, ways to generate e-revenue streams. And the COVID-19 pandemic is another business opportunity. Its not like theyve pivoted away from what they did in the past. If they were marketing stem cell treatments for Parkinsons disease, or ALS or spinal injuries, they havent stopped doing that. Theyve just added that theyve now got a stem cell treatment or an exosome therapy to treat or prevent COVID-19.

MP: They seem to be marketing their products primary as immune system boosters.

Leigh Turner

MP: At least one company is telling people that they should bank their stem cells to use as a treament if they get infected with the coronavirus.

LT: There are several business models at play right now. One is, come on in and get your stem cell immune booster to reduce your chances of getting COVID-19. They may also claim it will reduce your symptoms should you get it. Another marketing pitch is a bit more cautious. It says that if you come in now when youre in good health, they will bank your cells. Youll pay for the initial extraction of cells and also monthly or yearly for banking. The company then claims that should you fall ill with COVID-19 down the road, youll have those healthy cells available for you to use. Of course, they dont offer a lot of detail about how the cells would actually help you. You just supposed to take it for granted that they will.

MP: Theres no evidence of that.

LT: No. Its all just pseudoscience. But there is a meaningful hypothesis behind it. Thats how these businesses operate by fusing science with pseudoscience, credible research with junk claims.

MP: What is that hypothesis?

LT: There are companies and academic institutions right now that are interested in testing stem cell products, but not as immune boosters, not to prevent COVID-19 and not to eliminate the virus if someone gets infected. The studies right now are focusing on a very particular population of people with COVID-19 those who are typically in ICUs, suffering from acute respiratory distress syndrome. The hypothesis is that if certain types of stem cell products are administered to those people, we may be able to reduce inflammation in the lungs and help shorten the illness. But its a hypothesis.

MP: A good one?

LT: Its not an outrageous hypothesis. If you look at the existing literature, there have been studies done in the past that used stem cells for lung and respiratory disease. So far, those studies suggest that if you use clinical-grade stem cells and if you do it in a very rigorous way the safety profile is pretty good. But none of those studies has established extensive evidence of efficacy yet. Ideally, what you want is carefully designed, carefully conducted clinical trials testing that hypothesis and generating that evidence. These businesses the ones marketing stem cell therapies directly to individuals are not part of that scientific world.

MP: How do those businesses pull their customers in? How do they find them?

LT: They are typically big on social media. Im talking generally here, but they have Twitter accounts. They have YouTube channels. They have a Facebook page. Theyre not just putting up a website and hoping that somebody walks in the door. They hire social media marketing companies. They use marketing firms. They have pretty sophisticated marketing strategies that are tailored to particular demographics. It may be that they are targeting an elderly population, for example, because if youre interested in reaching people with COPD, youre not going to be trying to find 18-year-olds. Some businesses here in Minneapolis and elsewhere will have what they describe as educational seminars, which are basically infomercials. They are marketing events. They will try to get people to come to a convention center, a hotel [conference] room or a restaurant. Everything is free, but what theyll do is use hard-sell sales tactics to get people to commit, to write a check. Often theyll tell people that if they sign on today, theyll knock $2,000 or so off the price. But, of course, theyre not holding these events right now. They cant have these public gatherings.

MP: So, how are they selling people these products now, during the pandemic?

LT: More of it is happening online. One company, for example, uses a graduated pricing model. If its one person, its one price point. If its you and a family member, you both get a break on the procedure. And if its you and two additional family members, the price goes down even more. They use these things to try to get people to come in the door. One company in California has adapted to the pandemic in a different way. They have a do-it-yourself model. You dont have to even come into the clinic. You can buy their kit, and they ship it to your home. You then do the procedure at your dining room table.

MP: These stem cell products and treatments are quite expensive.

LT: Yes, some of the businesses Ive look at charge tens of thousands of dollars, although thats not necessarily for treating COVID-19. For COVID-19, it appears to be in the thousands-of-dollars category. In some cases, we dont know. The businesses can be pretty cagey. In some cases, they try to size up the customer and figure out how much they can extract from that person.

MP: Government agencies are cracking down on some of these stem cell businesses.

LT: The FDA (Food and Drug Administration), FTC (Federal Trade Commission) and Department of Justice have said that theyre going to be aggressive with dealing with these scams. And they have. Some businesses have already received letters from the regulators. That may be having a deterrent effect during the pandemic. Some businesses may want to jump in, but are afraid to do so. They may be waiting to see what happens before they take the chance.

MP: But the regulatory agencies are obviously not finding all of the businesses marketing unproven COVID-19 therapies.

LT: There is a lot of marketing fraud. And sometimes its quite challenging to figure out whats going on. Some of the clinics that I looked at didnt say, Were offering an immune booster for COVID-19. It was more just chatter. Clinics would put up a seven-minute video from one of their doctors about COVID-19 and emerging stem-cell research coming out of China, saying it was really encouraging. Then they would say, If you have any questions about stem cells and COVID-19, give us a call. So, whats the takeaway when a business does that? Does that mean they are selling stem cell treatments for COVID-19? Or are they just trying to get people to call? Its hard to know whats happening. If I had to guess, I say its a workaround. The businesses dont want to put it on their website, because thats too easy for someone from the FTC or the FDA to find. If they just put up a video, they can say theyre not marketing anything, that it was just meant to be educational.

MP: These businesses seem to rely on anecdotal cases or really small studies from China to support their claims.

LT: They use China in a couple of different ways. There was a case report, for example, that was published as a preprint. It wasnt published by a journal. It hasnt gone through peer review. It was just a preprint that someone put online. Its the case of a single individual with COVID-19 who received stem cells. Thats been written up in a very hyperbolic way, when really, its just a case report. Its one person. Some people get COVID-19 and recover anyway. You cant draw any conclusions from it about stem cells being efficacious, but its been written up that way. There was another study, very preliminary research, in which mesenchymal stem cells were administered to seven individuals with COVID-19 with various degrees of severity. A placebo was given to three individuals. The article doesnt provide the source of the stem cells. Nor does it provide much insight about the individuals who were given placebos, although they appear to be about 10 years older than [those receiving the stem cells]. It raises some interesting questions. It provides a basis for further research. But, unfortunately, some of the news media reports have been hyperbolic. Stem cell businesses use both these papers when marketing directly to consumers. They refer to these studies, and they also attach themselves to the bubbly media coverage.

MP: Consumers need to know that these products can be dangerous.

LT: Yes. The danger comes in several forms. Part of it is that these are financial scams lifting money off people who are worried and anxious. But, also, giving someone a product that hasnt been carefully tested in well-designed clinical trials raises a lot of concerns. Some businesses have released contaminated stem cell products into the marketplace. People end up getting infections and having to be hospitalized. It can be a very serious thing. Theres also the possibility that the wrong type of cell goes to the wrong part of the body and causes harm. When a company claims, for example, that a stem cell product will regenerate lung tissue and be an immune booster, one thing I would worry about is pulmonary embolisms. If someone is being given something that hasnt been thoroughly tested, its hard to know what would go wrong, but its easy to know something could go wrong.

FMI: Youll find the article on Cell Stem Cells website.

See the original post here:
Unproven stem cell products are being peddled as COVID-19 'therapies,' U of M researcher reports - MinnPost

Posted in Stem Cell Therapy | Comments Off on Unproven stem cell products are being peddled as COVID-19 ‘therapies,’ U of M researcher reports – MinnPost

Can stem cell therapy help – Greater Kashmir

Posted: May 18, 2020 at 11:46 am

Currently definitive treatment against civid is unavailable while patients are being offered palliative treatment to manage symptoms. Many known therapeutic agents like antivirals (Remdesivir or Hydroxychloroquine) or antiparasitic (Ivermectin) are being evaluated for their efficacy against the disease, although without any comprehensive success. Similarly, the exhaustive work is going on to develop the vaccine against the COVID-19 but that too requires lot more efforts and time. There is lot of buzz about the safety and efficacy of stem cell therapy in COVID-19 patients. Even some have claimed its efficacy far closer to the definitive treatment. The question is whether it really is the treatment of choice is being discussed here.

Stem cells are of various types including the embryonic cells (embryonic stem cells) and those harvested form the adult body tissues (like mesenchymal stem cells). Embryonic stem cells carry good differentiation potential as compared to the adult mesenchymal stem cells (MSCs). Due to the ethical and the teratogenic (tumour forming potential) issues MSCs are being favoured over embryonic stem cells (ESCs). MSCs additionally offer immuno-modulatory and / anti-inflammatory effects and can be harvested from numerous tissue sources including the foetal membranes. As MSCs are immune-compromised (weak potential to elicit immune response), there allogeneic (from other sources) utilization as ready-to-use source becomes possible. MSCs safety and efficacy in various non-infectious immune mediated diseases like Graft-vs-Host disease (GVHD) and Systemic Lupus Erythromatosis (SLE), among others has already been established. MSCs immune-modulation may be achieved either through the direct cell-to-cell contact or through their secretome being enhanced by the inflammatory mediators. Additionally, compared to the drugs that block inflammatory response (IL-6) like tocilizumab MSCs may prove superior by promoting healing of the damaged tissues through their tissue specific differentiation and recruitment of other pro-healing cells.

COVID-19 affects the elderly much more than the young ones and as much as 8 out of 10 patients above 65 years are hard hit. This is due to their weak immune response against the disease as compared to the young ones. In case of some young ones that gets badly affected, harmless genetic or environmental factors might make the immune response overdrive. The inflammatory cells secrete excessive quantity of cytokines without an ability to switch off and form a chain reaction leading to the cytokine storm. This unchecked inflammation and its mediators flood lungs and give rise to acute respiratory distress syndrome (ARDS). MSCs due to the characteristic immune-modulatory features may balance the immune response and prevent overdrive immune response in young ones while in case of elderly patients lack of the sufficient immune response may be compensated. It is worth mentioning here that MSCs directly may not affect the virus but due to their characteristic properties adverse reactions due to viral infection may be prevented.

MSCs are being categorized as Advanced Therapy Medicinal Products (ATMPs) by European Medicines Agency (EMA), meaning possible adverse reaction can arise with their use. Initial clinical trials conducted in China on COVID-19 patients have confirmed their safety and efficacy. Food and Drug Administration (FDA) as such has approved the compassionate use of the allogeneic MSCs. Stem cell therapy for COVID-19 is under clinical trials with little available data that confirms their safety and efficacy to treat the patients. These cells are being used in seriously ill patients due to unavailability of the specific treatment. MSCs clinical trials have been conducted in various parts of the world including the China, USA and Australia. Available reports of different allogeneic MSCs clinical trials have demonstrated improvement in seriously ill COVID-19 patients. Even COVID-19 patients with liver injury and cytokine storm too have been demonstrated to improve. At present MSCs approved compassionate (emergency) use is to prevent cytokine storm, however, the potential may go beyond and their applications can offer disease prevention as well.

MSCs as already discussed may not be free of risk. The recent evidences of disseminated intravascular coagulation (DIC) in COVID-19 demands further incites on MSCs applications as few experimental studies have reported intravascular coagulation with intravenous injection of MSCs. The under trial clinical studies vary from each other with respect to the patient inclusion and the doses of the cells given. The evaluation criteria need to be extensive, effective and uniform among the studies to develop evidence based medicine. It can be concluded that currently stem cell therapy for COVID-19 is under clinical trials and all the queries related to their safety, feasibility and efficacy need to be confirmed to arrive at any conclusion(s).

Dr Mudasir Bashir Gugjoo is Assistant Professor /Principal Investigator, Stem Cell Research Project FVSc & AH, SKUAST-Kashmir

Read more from the original source:
Can stem cell therapy help - Greater Kashmir

Posted in Stem Cell Therapy | Comments Off on Can stem cell therapy help – Greater Kashmir

R3 Stem Cell International Now Offering Enhanced Autism Stem Cell Program in Mexico – PR Web

Posted: May 18, 2020 at 11:46 am

Top Stem Cell Treatment for Autism in Mexico (888) 988-0515

SCOTTSDALE, Ariz. (PRWEB) May 18, 2020

R3 Stem Cell International is now offering an enhanced autism stem cell therapy program at its Tijuana regenerative clinic. There are two program options for patients and their families, which are all inclusive and represent extremely effective and safe cell counts.

While it is unclear exactly what causes Autism Spectrum Disorder (ASD), there are several recent clinical studies which have shown exciting outcomes for patients. Also, those studies have shown mesenchymal stem cell therapy for autism to be very safe as well.

R3 Stem Cell International's enhanced program provides umbilical cord derived stem cell therapy for patients, with total cell counts for the treatment ranging between 90 million up to 200 million live stem cells. The actual total administered depends on patient weight.

According to R3 International Medical Director Ramon De La Puerta, "We have seen exceptional outcomes for autism patients, which typically include increased cognitive abilities, interpersonal skills, less aggression and more. The biologics undergo quality assurance standards that exceed FDA regulations in the US, and no preservatives are used so cell viability is over 95%!"

The two all inclusive treatment options include either a five day stay, or several trips over a span of of a year. The all inclusive fee starts at $8975, and involves several IV therapies. Sedation is available with a highly qualified anesthesiologist if necessary, and parents are welcome to attend all treatment sessions.

As with all R3 Stem Cell International procedures, R3 takes care of concierge escort transportation from San Diego to the clinic, which is only 20 minutes from the SD International Airport. R3 will also help with travel logistics.

According to R3 CEO David Greene, MD, MBA, "Our enhanced Autism program offers an incredible opportunity for families desiring a safe, cost effective and clinically effective option for those who have not responded desirably with conventional treatments. Over 8 years of therapies, R3 has not seen any significant adverse events, and the patient satisfaction rate has been amazing!"

In order to find out if a person is a good candidate for stem cell therapy for Autism, R3 offers a free phone consultation for families simply by calling (888) 988-0515.

About R3 Stem Cell International: After 14,000 stem cell procedures in the US, R3 opened R3 Stem Cell International. With the first location in Tijuana, https://stemcelltreatmentclinic.com has been an incredible option for patients suffering from all types of chronic conditions such as kidney, liver, lung and heart issues. Additionally, neurologic issues respond well such as stroke, Alzheimer's, stem cells for diabetes and more.

Share article on social media or email:

The rest is here:
R3 Stem Cell International Now Offering Enhanced Autism Stem Cell Program in Mexico - PR Web

Posted in Stem Cell Therapy | Comments Off on R3 Stem Cell International Now Offering Enhanced Autism Stem Cell Program in Mexico – PR Web

Global Stem Cell Partnering Deals Collection (2010-2020): Access to Headline, Upfront, Milestone and Royalty Data – PRNewswire

Posted: May 18, 2020 at 11:46 am

DUBLIN, May 18, 2020 /PRNewswire/ -- The "Global Stem Cell Partnering Terms and Agreements 2010-2020" report has been added to ResearchAndMarkets.com's offering.

This report provides comprehensive understanding and unprecedented access to the stem cell partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter Stem Cell partnering deals. These deals tend to be multicomponent, starting with collaborative R&D, and proceed to commercialization of outcomes.

This report provides details of the latest Stem Cell agreements announced in the life sciences since 2010.

The report takes the reader through a comprehensive review Stem Cell deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Stem Cell partnering deals.

The report presents financial deal term values for Stem Cell deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.

The middle section of the report explores the leading dealmakers in the Stem Cell partnering field; both the leading deal values and most active Stem Cell dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.

One of the key highlights of the report is that over 600 online deal records of actual Stem Cell deals, as disclosed by the deal parties, are included towards the end of the report in a directory format - by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.

In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

The initial chapters of this report provide an orientation of Stem Cell dealmaking.

A comprehensive series of appendices is provided organized by Stem Cell partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Stem Cell partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Stem Cell technologies and products.

Analyzing actual contract agreements allows assessment of the following:

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/9pqrta

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets Laura Wood, Senior Manager [emailprotected]

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1904 Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

http://www.researchandmarkets.com

Read more here:
Global Stem Cell Partnering Deals Collection (2010-2020): Access to Headline, Upfront, Milestone and Royalty Data - PRNewswire

Posted in Stem Cell Therapy | Comments Off on Global Stem Cell Partnering Deals Collection (2010-2020): Access to Headline, Upfront, Milestone and Royalty Data – PRNewswire

How Mike Tyson is in such incredible shape at 53 thanks to new diet, cardio and weird stem cell tre – The Sun

Posted: May 18, 2020 at 11:46 am

MIKE TYSON has been doing the rounds to physically prepare for his sensational boxing comeback aged 53.

Tyson, who retired in 2005, has a whole new diet and cardio regime as well as going through a "weird" stem cell treatment.

3

It comes after the former heavyweight king announced plans to make a return to the ring to compete in exhibition bouts for charity, and has been training for the last month to do so.

Speaking to rapper LL Cool J on the Rock the Bells Radio show on SiriusXM, Tyson explained the methods he is using to get back into fighting shape, as he revealed: "Really I would just change my diet and just do cardio work.

"Cardio has to start, you have to have your endurance to go and do the process of training.

"So something to do is get in cardio, I would try and get two hours of cardio a day, make sure you get that stuff in. Youre gonna make sure youre eating the right food.

"For me its almost like slave food. Doing what you hate to do but doing it like its nothing. Getting up when you dont want to get up.

"Thats what it is. Its becoming a slave to life.

"Being a slave to life means being the best person you can be, being the best you can possibly be, and when you are at the best you can possibly be is when you no longer exist and nobody talks about you. Thats when youre at your best."

Tyson's return to training for the first time in 15 years has been aided by stem-cell research therapy, that has left him feeling like a "different person".

Stem-cell therapy is the use of stem cells to treat or prevent a disease or condition that usually takes the form of a bone marrow transplantation.

Tyson was asked whether that meant if his white blood had been spun and then put back in, to which he replied: "Yes. As they took the blood it was red and when it came back it was almost transfluid (sic).

"I could almost see through the blood, and then they injected it in me.

"And Ive been weird ever since, Ive got to get balanced now."

Having previously claimed he feels in the best shape of his life, Tyson revealed he will be ready to fight again in just six weeks.

He said: "My mind would belong to somebody that disliked me enough to break my soul, and I would give them my mind for that period of time.

"Six weeks of this and Id be in the best shape Ive ever dreamed of being in. As a matter of fact, Im going through that process right now. And you know what else I did, I did stem-cell research."

WHAT IS STEM CELL TREATMENT USED FOR?

Stem cell transplants are carried out when bone marrow is damaged or isnt able to produce healthy blood cells.

It can also be used to replace damaged blood cells as the result of intensive cancer treatment.

Here are conditions that stem cell transplants can be used to treat:

'OFFICIAL'Tyson return CONFIRMED as Briggs says the pair have officially signed to fight

TAKE ANYONE JONUFC star Jon Jones could beat Tyson and Ali in the SAME day, claims Sonnen

CANNON FODDERBriggs 'in talks with Tyson over charity fight' but fears he'll break a rib

SPAR DAYDid Joshua really beat up Fury over 3 rounds? Rivals recall last sparring session

NO W-HAYEHaye snubs Mike Tyson in top 5 heavyweights of all time and details sad decline

Pictured

GLOVES ARE OFFJoshua opponent Pulev's stunning ex Andrea accuses him of cheating

FIGHT FOR THE AGESHow heavyweights Tyson and Briggs compare with combined age of 101

WHAT A LEG-ENDFury reveals legs are 'f***ing killing' after brutal weekend training regime

PAC IT INMayweather insists young fighters calling out 'old' Pacquiao, 41, is 'sad'

Pictured

GARDEN PARTYEddie Hearn reveals plan to bring boxing back by hosting fights in his GARDEN

During his reign as champion, Tyson would wake up at 4.30am to run before later heading to the gym where he would do 10-12 rounds of boxing mixed in with an array of muscles exercises.

His diet consisted of 3000-4000 calories of carbohydrates and proteins which helped fuel his training sessions.

Tyson, still the youngest heavyweight champion of all time at 20, retired with a record of 50-6-2 and remains one of the most celebrated punchers of all time.

3

3

View post:
How Mike Tyson is in such incredible shape at 53 thanks to new diet, cardio and weird stem cell tre - The Sun

Posted in Stem Cell Therapy | Comments Off on How Mike Tyson is in such incredible shape at 53 thanks to new diet, cardio and weird stem cell tre – The Sun

Mike Tyson lifts lid on training regime and stem-cell therapy ahead of comeback – Metro.co.uk

Posted: May 18, 2020 at 11:46 am

Iron Mike will break his soul to get back in peak physical condition (Pictures: Instagram / @MikeTyson)

Heavyweight boxing legend Mike Tyson has explained his gruelling training regime as he bids to return to the ring and says he is still feeling weird after using stem-cell therapy.

The 53-year-old showed off his incredible, age-defying speed and power in training footage he uploaded to Instagram last week, declaring he was back and ready to take part in exhibition fights for charity.

Iron Mike has already been inundated with potential challengers to fight, with old heavyweight rival Evander Holyfield posting his own video in response to Tyson and opening the door to a potential third fight between the pair.

Joe Rogan recently suggested that Tysons incredible speed and power was not down to natural hard work alone, and now the veteran boxer has revealed the extreme lengths he is going to in order to get back in shape.

Speaking on the Rock the Bells Radio show on SiriusXM, Tyson was asked by rapper LL Cool J how he would get in peak shape in just six to eight weeks and replied: Really I would just change my diet and just do cardio work. Cardio has to start, you have to have your endurance to go and do the process of training.

So something to do is get in cardio, I would try and get two hours of cardio a day, make sure you get that stuff in. Youre gonna make sure youre eating the right food.

For me its almost like slave food. Doing what you hate to do but doing it like its nothing. Getting up when you dont want to get up. Thats what it is. Its becoming a slave to life.

People think a slave to life is just enjoying drugs and living your life. Being a slave to life means being the best person you can be, being the best you can possibly be, and when you are at the best you can possibly be is when you no longer exist and nobody talks about you. Thats when youre at your best.

Probed further on the mental aspect of preparing for a fight, Tyson continued: My mind wouldnt belong to me. My mind would belong to somebody that disliked me enough to break my soul, and I would give them my mind for that period of time.

Six weeks of this and Id be in the best shape Ive ever dreamed of being in. As a matter of fact, Im going through that process right now. And you know what else I did, I did stem-cell research.

After LL Cool J asked if that meant Tysons white blood cells had been spun and then put back in, Tyson continued: Yes. As they took the blood it was red and when it came back it was almost transfluid [sic], I could almost see through the blood, and then they injected it in me. And Ive been weird ever since, Ive got to get balanced now.

Tyson first revealed that he had undergone stem cell treatment which is usually used to treat or prevent a disease or condition in an Instagram live chat with Shaquille ONeal earlier this month.

You know what I had done? I had stem cell therapy, said Iron Mike. I feel like a different person but I cant comprehend why I feel this way. Its really wild what scientists can do.

MORE: Evander Holyfield demands bizarre no knockouts rule for potential Mike Tyson comeback fight

MORE: Joe Rogan shocked by fu*king sensational training videos of Mike Tyson

Follow Metro Sport across our social channels, on Facebook, Twitter and Instagram.

For more stories like this, check our sport page.

View post:
Mike Tyson lifts lid on training regime and stem-cell therapy ahead of comeback - Metro.co.uk

Posted in Stem Cell Therapy | Comments Off on Mike Tyson lifts lid on training regime and stem-cell therapy ahead of comeback – Metro.co.uk

Critical window for re-infection with HIV after stem cell transplantation – BioNews

Posted: May 18, 2020 at 11:46 am

18 May 2020

New research, in HIV positive patients being treated for blood cancer, has identified a critical time window after donor stem cell transplantation, during which the expanding donor cells are particularly vulnerable to being infected with HIV.

Patients with HIV who develop blood cancer may require treatment by allogeneic stem cell transplant, using bone marrow stem cells provided by a healthy donor. During a transplant, most of the patient's original immune cells are destroyed, and the immune system and blood cells are restored from the new donor stem cells.

'These results show a weak point that may explain why allogeneic stem cell transplants may not completely remove the virus from the body, despite a drastic reduction in the number of infected cells' saidsenior authorDr Julian Schulze zur Wiesch from the German Centre for Infection Research.

Stem cell transplantation in HIV positive patients has been the only medical intervention found to cure HIV (see BioNews 1039), however in nearly all cases HIV infection persists after transplantation.

In a new study it was discovered that immune cells generated from the donor stem cells are at risk of being infected with HIV during the first few weeks after transplantation.

In this study of 16 HIV positive participants with blood cancer, the researchers show that stem cell transplantation promotes reactivation of the virus within the patient's remaining original immune cells. This leads to some of the new immune cells becoming infected, thus 're-seeding' HIV within the host.

'Additional immunotherapy orgene therapy may be required to achieve ongoing, spontaneous control of HIV infection in people with HIV after allogeneic stem cell transplantation,' said Dr Schulze zur Wiesch.

This research was published in Science Translational Medicine.

See the original post here:
Critical window for re-infection with HIV after stem cell transplantation - BioNews

Posted in Stem Cell Therapy | Comments Off on Critical window for re-infection with HIV after stem cell transplantation – BioNews

Page 1,028«..1020..1,0271,0281,0291,030..1,0401,050..»